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Summary
Natural killer (NK) cells contribute to the effector phase of vaccine-
induced adaptive immune responses, secreting cytokines and releasing
cytotoxic granules. The proportion of responding NK cells varies between
individuals and by vaccine, suggesting that functionally discrete subsets of
NK cells with different activation requirements may be involved. Here, we
have used responses to individual components of the DTP vaccine [teta-
nus toxoid (TT), diphtheria toxoid (DT), whole cell inactivated pertussis]
to characterize the NK cell subsets involved in interleukin-2-dependent
recall responses. Culture with TT, DT or pertussis induced NK cell CD25
expression and interferon-c production in previously vaccinated individu-
als. Responses were the most robust against whole cell pertussis, with
responses to TT being particularly low. Functional analysis of discrete NK
cell subsets revealed that transition from CD56bright to CD56dim correlated
with increased responsiveness to CD16 cross-linking, whereas increasing
CD57 expression correlated with a loss of responsiveness to cytokines. A
higher frequency of CD56dim CD57 NK cells expressed CD25 and inter-
feron-c following stimulation with vaccine antigen compared with
CD56dim CD57+ NK cells and made the largest overall contribution to
this response. CD56dim CD57int NK cells represent an intermediate func-
tional phenotype in response to vaccine-induced and receptor-mediated
stimuli. These findings have implications for the ability of NK cells to
contribute to the effector response after vaccination and for vaccine-
induced immunity in older individuals.
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Introduction
Natural killer (NK) cells are classically regarded as a stable
population of innate immune effectors that, by cytokine
production or cytotoxicity, help to contain an infection or
limit tumour growth until an effective adaptive response is
mounted. However, numerous lines of evidence now sug-
gest that NK cells adapt functionally after stimulation by
viruses, cytokines and hapten antigens; this phenomenon
has been termed ‘NK memory’ but may also reflect func-
tional NK cell maturation.1 There are several routes by
which NK cell function may be enhanced during re-exposure
to a pathogen. Antigen-specific memory T cells secreting
interleukin-2 (IL-2) promote NK cell function and prolif-
eration, while pathogen-specific antibodies initiate anti-
body-dependent cellular cytotoxicity by cross-linking
CD16 or other Fc receptors for immunoglobulins.2–6
Alternatively, cytokines released during primary infection
may induce NK cells to proliferate and/or differentiate to
a more highly responsive state; subsets of NK cells express-
ing activating receptors able to bind specific pathogen
ligands may be particularly responsive (as described for
the Ly49H+ subset of mouse NK cells which bind the
murine cytomegalovirus m157 protein7).
Abbreviations: APC, allophycocyanin; DT, diphtheria toxoid; DTP, diphtheria–tetanus–pertussis; HCC, high concentration of
cytokines; HCMV, human cytomegalovirus; IFN-c, interferon-c; IL-2, interleukin-2; LCC, low concentration of cytokines; NK,
natural killer; PBMC, peripheral blood mononuclear cells; PE, phycoerythrin; rh, recombinant human; TT, tetanus toxoid
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A number of NK cell subsets with different functional
potential have now been described in humans. The least
mature circulating NK cells are CD56bright CD57 and
are assumed to give rise to CD56dim CD57 cells which,
in turn, mature into CD56dim CD57+ cells, the latter sub-
set increasing in frequency with increasing age.8,9 This
three-step maturation is associated with acquisition of
CD16, CX3CR1, granzyme and KIR, gradual loss of pro-
liferative capacity, reduced responsiveness to cytokines
such as IL-12 and IL-18, and increasing cytotoxic func-
tion.10,11 CD56dim CD57+ NK cells express lower levels of
IL-18Ra10,11 as well as lower levels of mRNA for the
inducible chain of the IL-12R (IL-12Rb2)12 suggesting
that these NK cells may respond less well than other sub-
sets to IL-12 and IL-18. Conversely, CD56dim CD57+ cells
express higher levels of CD16, suggesting that they may
be particularly good mediators of antibody-dependent
cellular cytotoxicity.12
The potential for NK cells to respond to exogenous
cytokines is central to their ability to control infec-
tions,4,13,14 particularly where ligands for other NK-acti-
vating receptors are lacking. Moreover, NK cells
responding to CD4+ T-cell-derived IL-2 have the poten-
tial to contribute to secondary immune responses, includ-
ing those induced by vaccination.3,4 We wondered,
therefore, whether NK cell subsets would differ in their
ability to mount ‘recall’ responses to vaccine antigens. To
test this hypothesis, we have assessed the capacity of vari-
ous NK cell subsets, defined principally by their expres-
sion of CD56 and CD57, to contribute to a recall
response to the components of diphtheria–tetanus–per-
tussis (DTP) vaccine. We find that vaccine-induced NK
cell interferon-c (IFN-c) and degranulation (CD107a)
responses differ between NK cell subsets. Importantly,
our studies reveal that CD57 expression is gained in a
gradual stepwise fashion and that changes in NK cell
function mirror this progressive maturation.
Materials and methods
Donors and peripheral blood mononuclear cell prepara-
tion
Volunteers were recruited from among staff and students
at the London School of Hygiene and Tropical Medicine.
All subjects gave fully informed, written consent and the
study was approved by the London School of Hygiene
and Tropical Medicine Ethics Committee. Subjects ranged
in age from 21 to 73 years and all donors confirmed that
they had been vaccinated against diphtheria, tetanus and
pertussis in childhood. Peripheral blood mononuclear
cells (PBMC) were separated by fractionation on a
Ficoll–Hypaque gradient and cryopreserved in liquid
nitrogen. Frozen PBMC were thawed with pre-warmed
complete medium [RPMI-1640 supplemented with
100 U/ml penicillin/streptomycin and 20 mM L-glutamine
(Gibco, Lifesciences, Paisley, UK) and 10% pooled human
AB serum (Sigma, Poole, UK)] (at 37°), washed several
times and rested for 30 min before use.
NK cell assay culture
Peripheral blood mononuclear cells (2 9 105 cells in
200 ll) were cultured in 96-well U-bottom plates in com-
plete medium with or without low concentration of cyto-
kines [LCC; 125 pg/ml recombinant human (rh) IL-12
(PeproTech, Rocky Hill, NJ) plus 10 ng/ml rhIL-18 (MBL,
Woburn, MA)]; high concentration of cytokines (HCC;
5 ng/ml rhIL-12 plus 50 ng/ml rhIL-18); or 75 lg/ml tet-
anus toxoid (TT), 1 lg/ml diphtheria toxoid (DT) or
1 IU/ml whole cell pertussis (all from the National
Institute for Biological Standards and Control, London,
UK) for 18 hr at 37°. GolgiPlug (containing Brefeldin A,
1/1000 final concentration; BD Biosciences, Oxford, UK)
and GolgiStop (containing Monensin, 1/1500 concentra-
tion; BD Biosciences) were added after 15 hr.
Receptor cross-linking
Flat-bottomed 96-well plates were coated (overnight at
4°) with 50 ll of mouse monoclonal antibody to human
CD16 (final concentration of 20 lg/ml; BD Biosciences)
or a cocktail of monoclonal antibodies to human NK
receptors [NKG2D, NKp30, NKp46, 2B4 (all from R&D
Systems, Abingdon, UK)] and CD2 (BD Biosciences) at an
overall combined concentration of 20 lg/ml, i.e. 4 lg/ml
each. An equivalent concentration of mouse IgG1 j iso-
type control antibody (BD Biosciences) was used as a
negative control. After washing (three times in sterile
PBS), 2 9 105 PBMC were added to each well and incu-
bated for 18 hr. GolgiPlug and GolgiStop were added
after 15 hr. Cells were then transferred to 96-well U-bot-
tomed plates for washing and staining.
Flow cytometry
Responses of NK cells and T cells were assessed as
described previously.15 Briefly, cells were stained with flu-
orophore-labelled monoclonal antibodies to cell surface
molecules, fixed, permeabilized and stained for intracellu-
lar molecules using a Cytofix/Cytoperm kit (BD Bioscienc-
es). Cells were analysed by flow cytometry on an LSR II
(BD Biosciences). Samples with fewer than 100 NK cells in
each subset were excluded. The following reagents were
used: anti-CD56-phycoerythrin (PE) -Cy7, anti-CD16-
allophycocyanin (APC) -H7, anti-CD4-Pacific Blue,
anti-IFN-c-e780, anti-IFN-c-APC, anti-CD3-V500 and
anti-CD69-phycoerythrin-cyanine5 (PE-Cy5) (all BD);
anti-CD8-PE-Cy5, anti-CD25-PE, anti-IL-18Ra-PE, anti-
CD62L-PE-Cy5, anti-CD57-e450 and anti-IL-2-APC (all
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e-Biosciences/Affimetrix, Hatfield, UK). Anti-IL-12Rb2
monoclonal antibody was obtained from R&D Systems
(Oxford, UK) and conjugated to PE-Cy5 using an Easylink
PE/Cy5 Conjugation Kit (Abcam, Cambridge, UK).
Data and statistics
Unless stated to the contrary, all figures show data from at
least three replicate experiments. Flow cytometry data were
analysed using FLOW JO (Tree Star, Ashland, OR) and data
were analysed using PRISM6 (GraphPad, San Diego, CA)
software. Statistical comparisons were performed by paired
analysis of variance or t-tests. Correlation between param-
eters was by bivariate regression analysis. ****P ≤ 00001,
***P < 0001, **P < 001, *P < 005.
Results
DTP vaccination induces durable vaccine antigen-
driven NK cell responses
To validate DTP vaccination as a suitable model for eval-
uating NK cell recall responses, PBMC were incubated
overnight with TT, DT or inactivated whole cell pertussis
with or without low concentrations of the cytokines IL-12
and IL-18 (LCC) or, as a positive control, with a high
concentration of cytokines IL-12 and IL-18 (HCC),
stained for NK cell phenotypic and functional markers,
and examined by flow cytometry (Fig. 1). HCC induces
over 50% of CD3 CD56+ NK cells to express cell surface
CD25 and intracellular IFN-c (median 199%, range 16–
575, Fig. 1a–c) and has a significant, but much less
marked, effect on CD107a expression (median 25%,
range 0001–90, Fig. 1a,d,e). By contrast, LCC alone
induces a small, but significant, proportion of NK cells to
express CD25 (median 64%, range 06–254), but few, if
any, of these cells also produce IFN-c (median 00%,
range 00–168) or express CD107a (median 04%, range
01–24) on their surface (Fig. 1a).
Among PBMC stimulated with vaccine antigen alone
(i.e. without LCC) there is highly significant up-regula-
tion of both CD25 and IFN-c by NK cells in response to
pertussis (median 13%, range 00–46), a lesser (but still
significant) response to DT (median 01%, range 00–13)
and no significant response to TT (median 01%, range
00–13) (Fig. 1b). However, responses to all three anti-
gens were significantly enhanced in the presence of LCC
(pertussis: median 39%, range 09–176; DT: median
05%, range 00–135; TT: median 03%, range 00–213)
(Fig. 1c) and were ablated in the presence of neutralizing
antibody to IL-2 (data not shown). These data are fully
consistent with a scenario in which a whole cell antigen
such as pertussis contains ligands for Toll-like receptors16
and so induces accessory cells to secrete cytokines such as
IL-12 and IL-18, whereas purified proteins such as TT
and DT do not; exogenous LCC induces expression of
CD25 (and so the high-affinity IL-2R) on NK cells allow-
ing them to respond to IL-2 from vaccine-specific CD4+
T cells. By contrast, a statistically significant increase in
CD107a expression on NK cells was seen in response to
all three vaccine components (pertussis: median 22%,
range 02–222; DT: median 05%, range 00–26; TT:
median 05%, range 00–43) (Fig. 1d) and this was not
significantly enhanced by LCC (pertussis: median 45%,
range 09–200; DT: median 09%, range 00–30; TT:
median 06%, range 01–25) (Fig. 1e).
CD57 is a stable marker of human NK cell subsets
Despite very robust NK cell responses to some of the vac-
cine antigens, not all NK cells responded and there is
considerable heterogeneity in the magnitude of the NK
cell response between donors (Fig. 1b–e). Although heter-
ogeneity between individuals might be explained by varia-
tion in the strength of the T-cell IL-2 response that drives
the NK responses,3,17,18 this is unlikely to explain hetero-
geneity of responses within the NK cell population of an
individual donor. We therefore considered whether
within-donor variation might be the result of differences
between subsets of NK cells in their intrinsic sensitivity to
activation by monokines and T-cell-derived IL-2.
CD57 is a marker of highly differentiated, highly cyto-
toxic NK cells12,19,20 and CD62L (L-selectin) is a marker of
cells able to proliferate and secrete IFN-c after high-dose
cytokine stimulation.21 However, to use these as markers
of NK cell subsets in mixed PBMC assays, it was impor-
tant to know whether they were stable phenotypic markers
or whether their expression was altered after activation. To
this end, expression of CD62L and CD57 were examined
on PBMC after overnight stimulation with LCC or HCC,
or with cross-linking antibody to the NK cell activating
receptor CD16, or a cocktail of antibodies to NK cell acti-
vating receptors (NKp30, NKp46, NKG2D and CD2)
(Fig. 2). Consistent with previous reports,12 CD62L and
CD57 tended to define mutually exclusive subsets of NK
cells (Fig. 2a). However, although CD57 expression
appeared very stable after overnight activation by cyto-
kines or receptor cross-linking (Fig. 2b), CD62L expres-
sion was markedly reduced after activation (Fig. 2c).
Given the significant activation-induced down-regulation
of CD62L, subsequent functional analysis of NK subsets
was based on CD57 expression but not CD62L.
CD56 and CD57 define multiple distinct NK cell
subsets
Expression of CD56 and CD57 has been used to identify
three subsets of NK cells. Functional analysis of these
subsets suggests that NK cells differentiate from relatively
immature CD56bright CD57 cells, which respond to
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cytokine stimulation by producing IFN-c but have limited
cytotoxic potential, to CD56dim CD57 cells which are
also poorly cytotoxic but retain IL-12R expression and so
the ability the secrete IFN-c in response to cytokine
stimulation and, eventually, to CD56dim CD57+ cells,
which no longer respond to exogenous cytokines but are
skewed towards a cytotoxic phenotype following cross-
linking of CD16 or NK receptors or exposure to target
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Figure 1. Natural killer (NK) cell responses to diphtheria toxoid (DT), tetanus toxoid (TT) and whole cell pertussis. Peripheral blood mononu-
clear cells (PBMC) from previously vaccinated donors were cultured in vitro for 18 hr with medium alone, low concentration of cytokines
(LCC), DT, TT, pertussis (Per), DT + LCC, TT + LCC, Per + LCC, or high concentration of cytokines (HCC). (a) Representative flow cytometry
plots showing gating of CD56+ CD3 NK cells and expression of CD25, CD107a and interferon-c (IFN-c). (b, c) Percentage of NK cells co-
expressing CD25+ and IFN-c+ after stimulation in the absence (b) or presence (c) of LCC. (d, e) Percentage of NK cells expressing CD107a after
stimulation in the absence (d) or presence (e) of LCC. Note: in (b) and (c) HCC data are shown on a different axis (see right hand side of plot).
Each data point represents one donor, n = 22. Lines represent median values. Data were analysed with paired, non-parametric t-tests.
**** P ≤ 00001, *** P < 0001, ** P < 001, * P < 005.
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cells.10,12,20 However, CD57 expression is not simply ‘off’
or ‘on’ but is gradually up-regulated in a stepwise fashion
(Fig. 3). It was possible to identify seven distinct peaks of
CD57 expression (Fig. 3b,c) with each peak accounting
for ~5% to ~35% of all CD56dim NK cells (Fig. 3d).
CD62L expression is lost as soon as cells begin to express
CD57 (Fig. 3e) but CD16 expression is gradually up-reg-
ulated, with maximal CD16 expression not being reached
until the third peak of CD57 expression (Fig. 3f). Most
importantly, the functional remodelling of NK cells, in
terms of loss of cytokine-induced up-regulation of CD25
and IFN-c expression, is extremely gradual with complete
unresponsiveness to HCC not being seen until CD57
expression reaches its maximal level (Fig. 3g,h). By con-
trast, little or no difference was observed in the ability of
NK cells with different levels of CD57 expression to
degranulate in the presence of cytokines (Fig. 3i).
These data suggest that NK cells with intermediate levels
of CD57 expression (CD57int), which represent a signifi-
cant fraction (~30%) of circulating NK cells, are also inter-
mediate in terms of their functional maturation. To
formally test this hypothesis, we analysed responses of the
four NK cell subsets (CD56bright; CD56dim CD57;
CD56dim CD57int and CD56dim CD57+, Fig. 4a) to HCC,
cross-linking of CD16 and cross-linking of NK receptors,
by expression of CD25, IFN-c or CD107a (Fig. 4b–d). As
expected, high proportions of CD56bright cells expressed
CD25, IFN-c or CD107a in response to HCC; cross-link-
ing of CD16 or NK cell receptors up-regulated CD25 and
CD107a but not IFN-c in this subset (Fig. 4b–d). Among
CD56dim NK cells, CD25, CD107a and IFN-c responses to
HCC declined with increasing levels of CD57 expression
with a statistically significant negative trend from
CD56dim CD57 cells, through CD56dim CD57int cells to
CD56dim CD57+ cells (analysis of variance for all linear
trends, P ≤ 00001) (Fig. 4b–d). Interestingly, although no
significant differences were observed between the three
CD56dim populations in their ability to degranulate or
produce IFN-c in response to CD16 or NK cell receptor
cross-linking, the cross-linking of CD16 or NK cell recep-
tors led to increasing levels of CD25 expression with
increasing expression of CD57 (linear trend; P ≤ 00001 in
both cases), suggesting that responsiveness to T-cell IL-2
may be retained in CD57+ NK cells in the presence of
antibodies able to induce antibody-dependent cellular
cytotoxicity. In summary therefore, the transition from
CD56bright to CD56dim (irrespective of CD57 expression) is
coincident with a marked reduction in cytokine secretion,
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Figure 2. CD57 is a stable marker of human natural killer (NK) cell subsets. Peripheral blood mononuclear cells (PBMC) were cultured in vitro
for 18 hr with plate-bound mouse IgG1 isotype control (mIgG1), anti-human CD16, anti-human NK cell receptor (NKR) cocktail (a–CD2,
a–NKG2D, a–NKp30, a–NKp46) (all to a final concentration of 20 lg/ml), low concentration of cytokines (LCC) or high concentration of cyto-
kines (HCC). (a) Representative flow cytometry plots showing expression of CD62L and CD57 on gated (CD56+ CD3) NK cells. (b) Percentage
of NK cells that were CD57+ after PBMC culture under different conditions. (c) Percentage of NK cells that were CD62L+ after PBMC culture
under different conditions. P-values are derived from repeated measures analysis of variance (c). Each data point represents one donor, n = 31.
Lines represent mean values. ****P ≤ 00001, **P < 001, *P < 005.
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but no overall change in degranulation, in response to
cross-linking of NK cell receptors or CD16 receptors. By
contrast, increasing CD57 expression correlates with a
gradual loss of responsiveness (in terms of CD25 expres-
sion, IFN-c release and degranulation) to exogenous
IL-12 + IL-18.
Vaccine-driven, cytokine-mediated NK cell IFN-c
responses are dominated by the CD56dim CD57 and
CD56dim CD57int NK cell subsets
Accessory cytokines (including IL-12 and IL-18) and
T-cell-derived IL-2 are known to be essential to drive NK
cell IFN-c responses during re-stimulation with vaccine
antigens.3 Given that increasing CD57 expression corre-
lates with loss of responsiveness to HCC, we predicted
that CD56dim CD57 or CD56dim CD57int NK cell popu-
lations would show stronger ‘recall’ responses to whole
cell pertussis than would CD56dim CD57+ NK cells. To
test this hypothesis, responses to pertussis (Fig. 1) were
analysed for each of the four NK cell subsets defined by
CD56 and CD57 expression (Fig. 5). There was a clear
hierarchy of responses with a significantly higher propor-
tion of CD56dim CD57 NK cells than CD56dim CD57int
or CD56dim CD57+ NK cells co-expressing CD25 and
IFN-c (P < 0001 for linear trends) (Fig. 5a). On the
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Figure 3. CD56 and CD57 define multiple distinct natural killer (NK) cell subsets. Representative flow cytometry plots showing gating of
CD56bright and CD56dim NK cells (a) and corresponding dot plot (b) and histogram (c) showing gating of the CD56dim subset into seven subpop-
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subpopulation. Bar charts represent means  SEM, n = 32.
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other hand, CD107a expression was similar among all
three CD57-defined NK cell subsets (Fig. 5b). When con-
sidering the proportion of all NK cells belonging to each
subset together with the responsiveness of each individual
subset, it became evident that vaccine antigen-driven NK
cell IFN-c recall responses occur almost entirely within
the CD56bright and CD56dim CD57 NK cell subsets with
minimal contributions from the CD56dim CD57int and
CD56dim CD57+ subsets (Fig. 5c).
CD57 acquisition is associated with reduced
expression of cytokine receptors IL-12Rb2 and
IL-18Ra
CD57 acquisition on NK cells is associated with a reduced
ability to respond to accessory cytokines (Fig. 4) leading
to a progressive decline in their ability to respond to vac-
cine-driven cellular responses by production of IFN-c
(Fig. 5a). To determine whether this is due to altered cyto-
kine receptor expression and altered downstream signal-
ling we assessed the resting (ex vivo) expression of
IL-18Ra and IL-12Rb2 (Fig. 6). The proportion of
IL-12Rb2-expressing cells was highest among the
CD56bright NK cells with a progressive decrease in expression
across the CD57-defined NK cell subsets (Fig. 6b) but
IL-12Rb2 expression density did not vary across subsets
(Fig. 6c). Although IL-18Ra was expressed at a much
higher frequency than IL-12Rb2 within all NK cell subsets,
the same trend was seen, with declining IL-18Ra expres-
sion, with increasing CD57 expression (Fig. 6d). In contrast
to IL-12Rb2, however, IL-18Ra mean fluorescence intensity
also declined with increasing CD57 expression (Fig. 6e).
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Discussion
Vaccination typically provides long-lasting protection
against infectious diseases by inducing the expansion and
differentiation of small populations of naive, antigen-spe-
cific, T and B cells into much larger populations of long-
lived memory cells with enhanced effector function. In
particular, antigen-specific memory CD4+ T cells augment
B-cell, CD8+ T-cell and macrophage-mediated effector
functions.22 Although circulating antibody may persist for
many years after vaccination, frequencies of antigen-spe-
cific memory T cells are typically extremely low in
peripheral blood (approximately 1 in 10 00023) and can
be difficult to detect in the absence of recent boosting.
However, the observation that IL-2 produced in an anti-
gen-specific manner by CD4+ T cells can activate a sub-
stantial proportion (varying from ~ 1% up to 60% in
some cases) of all circulating NK cells,2,3,13,18,24 and that
these responses can be detected for more than 20 years
after vaccination in the case of DTP, suggests that NK cell
responsiveness might represent a more sensitive biomar-
ker of T-cell induction and maintenance and might there-
fore have a role to play in evaluation of new vaccines or
new vaccine formulations. Whether NK cells – activated
by T-cell IL-2 or by cross-linking of Fc receptors (CD16)
by immune complexes – play an important role as effec-
tors of vaccine-induced immunity is as yet unknown but
the speed with which they are activated (within 6 hr of
exposure to the pathogen3) and the large number of
potentially responding cells suggest that their role should
be investigated.
Here, we observed that NK cell responses to pertussis
were significantly greater in magnitude than responses to
DT or TT, even though all three antigens would have
been administered together during vaccination. A likely
explanation for this is that the pertussis antigen is a
whole cell preparation containing numerous ligands for
pattern recognition receptors on macrophages and den-
dritic cells, leading to their secretion of IL-12 and IL-18,
which is necessary to induce NK cells to secrete IFN-c
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and become cytotoxic.4,13 Purified toxoids such as DT
and TT lack such ligands and so, in vitro at least, NK cells
can only be induced to respond in the presence of exoge-
nous IL-12 and IL-18. In vivo. however, infection by live
tetanus and diphtheria bacteria would presumably induce
a strong accessory cell cytokine response. On the other
hand, much stronger NK responses to pertussis than DT
or TT were seen even in the presence of LCC, suggesting
that whole cell pertussis may also induce a stronger T-cell
response than does a toxoid antigen.
Despite an overall tendency for NK cells to respond to
vaccine antigens, there was considerable heterogeneity
between individuals, which may in part be explained by
inter-individual variation in T-cell IL-2 responses. How-
ever, we also observed heterogeneity between NK cell
subsets in their responsiveness to vaccine-driven signals,
with responses being dominated by CD56bright CD57
and CD56dim CD57 NK cells. This correlated with
higher levels of CD25 expression on IL-12/IL-18-activated
CD57 cells compared with CD57+ cells and a higher
resting level expression of IL-12Rb2 and IL-18Ra on these
cells. The relationship between NK cell phenotype and
responsiveness to exogenous cytokines is summarized in
Fig. 7. These findings are in line with previous reports
that CD57+ NK cells are less able to respond to cyto-
kines,10,12 and express lower levels of IL-18Ra and lower
amounts of mRNA for IL-12Rb2, compared with CD57
NK cells. IL-18 is known to induce expression of the
high-affinity IL-2Ra (CD25) on NK cells25 whereas IL-12
is necessary, but not sufficient, for their production of
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IFN-c.26 Moreover, IL-2 induces expression of the induc-
ible chain of the IL-12R (IL-12b2).27 Thus, as shown
here, synergy between these three cytokine signals, IL-2,
IL-12 and IL-18, results in NK cells producing high levels
of IFN-c during the first 18–24 hr following re-exposure
to vaccine antigens.
Interestingly, we have observed that the maturation of
NK cells from CD56bright CD57 to CD56dim CD57+ is a
gradual process with functional changes being highly cor-
related with CD56 and CD57 expression. This is particu-
larly apparent for the cytokine-driven pathway of NK cell
activation where expression of IL-12R and IL-18R as well
as IL-12/IL-18-induced CD25 expression and IFN-c syn-
thesis are all very tightly negatively associated with CD57
expression. We find that CD57int NK cells make signifi-
cant amounts of IFN-c after stimulation with high-dose
IL-12/IL-18 but respond less robustly to low concentra-
tion cytokines and vaccine antigens, suggesting that they
may fail to compete effectively with CD57 NK cells
when cytokines are limiting.
An area of increasing concern in industrialized countries
is the burden of infectious disease and poor response to
vaccination in the elderly population.28 Although ageing in
the innate immune system, including age-associated
changes in the composition, phenotype and function of
circulating NK cells, is being linked to increased suscepti-
bility to de novo viral and bacterial infections,29 deteriora-
tion of antigen-specific memory responses and reduced
responsiveness to vaccination with increasing age tend to
be attributed to narrowing of the T-cell repertoire and
functional senescence of the T-cell pool.30,31 Our data sug-
gest, however, that these two components of immune age-
ing may interact; deteriorating CD4+ T-cell responses will
limit the availability of IL-2 to drive NK cell responses
while, at the same time, the proportion of CD57 NK cells
able to respond to IL-2 will decrease. We predict, therefore,
that vaccination-induced NK cell IFN-c responses could
decline with increasing age, potentially contributing to
reduced vaccine efficacy in elderly populations. In addi-
tion, subclinical human cytomegalovirus (HCMV) infec-
tions may potentiate the functional differentiation and
senescence of NK cells.9,32–35 Given that at least 40% of the
world population is HCMV seropositive, and prevalence
can exceed 95% in some African and Asian populations,36
HCMV exposure may contribute significantly to poor vac-
cine efficacy at a population level. Studies to test these vari-
ous predictions are currently underway in our laboratory.
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